Dr. Fleur-Lominy on the Current Sequencing Strategy in MPNs

Partner | Cancer Centers | <b>Perlmutter Cancer Center at NYU Langone</b>

Shella Saint Fleur-Lominy, MD, PhD, discusses the current sequencing strategy in the treatment of patients with myeloproliferative neiplasms.

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor, Department of Medicine, at NYU Langone Health’s Perlmutter Cancer Center, discusses the current sequencing strategy in the treatment of patients with myeloproliferative neiplasms (MPNs).

In MPNs, if they are a transplant candidate, it is preferred to take them to transplant depending on the risk level, unless observation is appropriate, says Fleur-Lominy. Some patients can be observed because they are asymptomstic. However, when these patients start developing symptoms, transplant should not be delayed. Transplant should be the first option, and then a JAK inhibitor can be given later if the patient relapses or experiences disease progression, concludes Fleur-Lominy.